CTBP1-AS2
ctBP1-AS2: A Long Non-Coding RNA with Diverse Roles in Human Health and Disease
Description
ctBP1-AS2 (Carboxyl-Terminal Binding Protein 1 Antisense RNA 2) is a highly conserved long non-coding RNA (lncRNA) located on chromosome 4q24. It is composed of approximately 1,400 nucleotides and exhibits a wide range of expression patterns across different tissues and cell types. ctBP1-AS2 has been found to play critical roles in various biological processes, including gene regulation, cellular differentiation, and RNA stability.
Mechanism of Action
ctBP1-AS2 has multiple mechanisms of action, depending on its cellular context and molecular interactors. It can function as a transcriptional activator or repressor by regulating the expression of specific target genes. It has also been shown to interact with microRNAs (miRNAs) and other non-coding RNAs, modulating their stability and function. Additionally, ctBP1-AS2 can bind to proteins, including transcription factors and chromatin modifying enzymes, influencing their activity and cellular localization.
Associated Diseases
Aberrant expression or mutation of ctBP1-AS2 has been linked to a number of human diseases, including:
- Cancer: ctBP1-AS2 has been implicated in the development and progression of various cancers, including lung cancer, breast cancer, and hepatocellular carcinoma. It can promote tumor cell proliferation, invasion, and metastasis, as well as inhibit apoptosis.
- Neurodegenerative diseases: Dysregulation of ctBP1-AS2 has been observed in patients with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). It is believed to affect neuronal survival, differentiation, and synaptic plasticity.
- Cardiovascular diseases: ctBP1-AS2 has been found to be involved in the regulation of cardiac function and is associated with heart failure and cardiomyopathy.
- Metabolic disorders: ctBP1-AS2 expression is altered in obesity and diabetes, suggesting a potential role in metabolic regulation.
Did you Know ?
A study published in the journal Nature found that in patients with lung cancer, high levels of ctBP1-AS2 were associated with a 2.5-fold increased risk of metastasis and a 1.7-fold increased risk of death compared to patients with low levels.
